Evotec, Apeiron Biologics enter collaboration

Evotec AG (Frankfurt:EVT) (TecDAX) today announced that it has entered into a collaboration with Apeiron Biologics AG, to initially identify small molecule modulators of DREAM (Downstream Regulatory Element Antagonistic Modulator), a novel target involved in perception of various pain mechanisms. Further projects will be evaluated to potentially expand this cooperation in due course.

Evotec will apply, in a first instance, its expertise in cellular assay development with opportunities for the project to rapidly move into hit identification and beyond.

Dr Hans Loibner, Chief Executive Officer at Apeiron Biologics, commented: "Combining our two companies' skills is an excellent way to move forward with this innovative and promising project. We have worked with Evotec in the past and continue to be impressed by the quality of the work performed there."

Dr Werner Lanthaler, Chief Executive Officer at Evotec, stated: "Apeiron is certainly one of the most exciting young biotech companies in Europe. We are happy that through the optimal use of R&D outsourcing Evotec can add value here."

No financial details are disclosed.

Source:

 EVOTEC AG

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Fully reduced form of vitamin K found to efficiently inhibit ferroptotic cell death